The patient in the clinic was 22, eight weeks postpartum with her second child, and exhausted. She came in asking for birth control, but her schedule made standard oral contraceptives a gamble. Traditional progestin-only pills, the standard option for many nursing mothers, come with a notoriously unforgiving three-hour administration window. Take the pill at 8:00 a.m., and by 11:01 a.m., its contraceptive efficacy drops off a cliff. For a mother managing a newborn’s chaotic sleep schedule, hitting a three-hour target every day isn’t just difficult; it is functionally impossible.
There was an obvious alternative: drospirenone, a newer progestin-only option with a 24-hour missed-pill window and reliable ovulation suppression independent of breastfeeding status. It offered the exact safety margin she needed. I wrote the prescription, handed her the summary, and considered the clinical encounter complete.
Two days later, the pharmacy rejection notice arrived. Coverage denied. Prior authorization required.
When the prior authorization appeal hit a dead end, I realized I was fighting the wrong target. The rejection hadn’t come from a medical director carefully weighing this patient’s chart; it was decided months prior in a quiet conference room by the state’s Department of Social Services Pharmacy & Therapeutics (P&T) Committee.
Most physicians go through residency without ever hearing the acronym P&T, let alone knowing who sits on the committee. These bodies composed of pharmacists, state administrators, and appointed physicians determine the Preferred Drug List for health plans and state Medicaid programs. They decide which medications pass through with a single electronic signature, and which require administrative hurdle-jumping. They make decisions that govern thousands of patients, yet almost no medical curriculum explains how they operate or how a practicing physician can walk into the room.
Complaining about prior authorization is a universal pastime in hospital breakrooms. We trade stories of bureaucratic walls, write angry appeal letters, and ultimately pivot to a second- or third-choice drug. But complaining treats the friction as an unavoidable weather pattern rather than a decision someone made.
I didn’t know how to challenge a formulary until an attending casually mentioned that state Medicaid agencies are required by law to hold open public meetings and periodically review drug classes. I looked up the Connecticut Department of Social Services schedule and saw that contraceptive agents were up for their scheduled review. The door was open; nobody had ever bothered to tell us.
Navigating the process meant learning a dialect they don’t teach in medical school. Instead of submitting another individual appeal, I spent off-duty hours drafting a formal physician policy memorandum. I focused on the stark clinical difference between a three-hour and a 24-hour missed-pill window, the physiological realities of the postpartum period, and the preventable costs of unintended, short-interval pregnancies.
When I asked colleagues across the state to sign on or testify, the initial reaction was skepticism. “They’ve already made up their minds,” one primary care attending told me. But as I explained the clinical gap, that skepticism turned into action. Family planning specialists, generalist ob/gyns, and PCPs agreed to submit clinical statements. Still, sitting in the hearing room waiting to testify, I had an uneasy knot in my stomach about whether a panel of state administrators would care about the daily realities of our labor ward and outpatient clinics.
We presented the evidence dossier and testified before the committee. In May 2025, the committee voted to add drospirenone to the Connecticut Medicaid Preferred Drug List, removing the prior authorization requirement for HUSKY-insured patients statewide.
A few weeks ago, I saw another postpartum patient in clinic. Her situation was nearly identical to the first: erratic hours, high stress, and a clear need for a reliable, forgiving contraceptive option. I wrote the prescription for drospirenone, submitted it, and moved on to the next room.
When she picked up her medication that afternoon, no one explained the committee meetings, the policy briefs, or the administrative votes that took place months prior. She didn’t need to know any of it.
The victory was satisfying, but the underlying lesson was sobering. The clinical barrier hadn’t existed because the committee held an anticontraceptive stance; it existed because no active clinician had previously brought front-line data to the table. The gatekeepers of care are often not guideline panels, but administrative committees waiting for clinicians to show up.
This dynamic isn’t unique to ob/gyn. Every specialty operates within boundaries set by formulary committees and hospital pharmacy boards. Whether it is a cardiology fellow trying to get a novel heart failure drug covered or a rheumatologist fighting for a specific biologic, the gap between what guidelines recommend and what patients actually receive is dictated by these unseen bodies.
Yet, physicians are rarely taught to view formulary advocacy as part of their job. We are trained to advocate fiercely for the individual patient in front of us, but we are seldom taught how to navigate the systems that dictate what is possible for thousands of patients at once. Formulary literacy — understanding how drugs are selected, how preferred lists are structured, and how to formally petition for change — should be as foundational to medical training as learning to navigate an EHR.
Do you know who makes the formulary decisions affecting your patients? Share in the comments.
